ZEJULA is a once-daily, oral maintenance treatment for women with newly diagnosed advanced or recurrent ovarian cancer, after the cancer has completely or partially responded to the most recent chemotherapy.
Take ZEJULA at home, or wherever you are.
That leaves more of your day to focus on what matters to you.
ZEJULA may offer more time without your cancer recurring,*
regardless of certain genetic characteristics, like BRCA status
ZEJULA is used as a maintenance treatment for women with and without a positive test for BRCA or HRD.†‡
*In a first-line maintenance clinical trial, ZEJULA delayed disease progression for a median of 14 months vs 8 months with placebo. In a recurrent maintenance clinical trial, ZEJULA delayed disease progression in patients with an inherited BRCA mutation for a median of 21 months vs 6 months with placebo. In patients without an inherited BRCA mutation, ZEJULA delayed disease progression for a median of 9 months vs 4 months with placebo. Results may vary. Median is the middle number in a set of data, also called the midpoint. The trials are ongoing to see if patients live longer overall with treatment.
†HRD, or homologous recombination deficiency, occurs when cells have difficulty repairing themselves and appears in about 50% of women with ovarian cancer.
‡BRCA refers to a set of genes called BRCA1 and BRCA2. Mutations in BRCA genes increase a woman’s risk of developing ovarian cancer, but having a BRCA mutation does not mean a woman will develop ovarian cancer. BRCA mutations can be inherited, or passed from parents to their children.
ZEJULA is a treatment option for certain women with advanced ovarian cancer.
ZEJULA can be used as a:
First-Line Maintenance Treatment
For recently diagnosed advanced ovarian cancer that has responded (complete or partial response) to platinum-based chemotherapy
Recurrent Maintenance Treatment
For recurrent ovarian cancer that has responded (complete or partial response) to platinum-based chemotherapy
For HRD+ advanced ovarian cancer§ after 3 or more prior chemotherapy regimens
§HRD+ advanced ovarian cancer is defined as tumors with a certain BRCA gene mutation, or gene mutation problems in patients who have progressed more than 6 months after their last treatment with platinum-based chemotherapy. Your healthcare provider will perform a test to make sure that ZEJULA is right for you.